Genetic testing changes breast cancer focus The Augusta Chronicle Two appear to target the HER2 marker but one, called everolimus, is aimed at breast cancers without HER2 but that are estrogen-positive and whose disease has spread, Samuel said. Many times those patients are receiving hormonal treatments that the ... |
